



ASX RELEASE

Volpara Health signs collaboration agreement with Riverain Technologies to drive expansion into US lung cancer screening market

Highlights:

- **Volpara cements its expansion into the lung cancer screening market with collaboration agreement with leading US-based lung imaging company Riverain Technologies**
- **Riverain Technologies are leaders in the application of AI to lung nodule detection**
- **Partnership will enable lung cancer screening programs to have access to expanded, more integrated services for patient reporting and tracking, cancer risk assessment, and nodule detection**
- **Volpara entered the lung cancer screening market with its June 2019 acquisition of MRS Systems, Inc.**
- **Volpara's patient reporting, tracking, and risk assessment software, Volpara® Lung™, covers ~8% of US lung cancer screening**
- **Lung cancer causes ~130,000 deaths each year in the US alone, including ~60,000 women**
- **Lung cancer CT screening programs are expanding and developing globally, with ~15M people now eligible in the US and reimbursement set at ~US\$250 per scan**

Wellington, NZ, 8 September 2021: Volpara Health Technologies ("Volpara," "the Group," or "the Company"; ASX:VHT), a global health technology software leader providing an integrated platform for personalised breast care, today announces it has commenced the expansion of its software platform into the lung cancer screening market, signing a collaboration agreement with Ohio-based Riverain Technologies ("Riverain"). Volpara entered the market in June 2019 with the acquisition of Aspen® Lung from MRS Systems, Inc.

Volpara Lung is an advanced, integrated, and adaptable reporting, tracking, and risk assessment solution for lung cancer screening that enables patient management from scheduling to diagnosis. The software offers structured reporting, customisable reminders, and more than 40 statistical reports to monitor and track patients— a critical service for outreach to patients who are overdue for their screening or follow-up exams.

Volpara Lung automatically collects and validates all the required data elements for successful submission to the American College of Radiology Lung Cancer Screening Registry® for reimbursement.

Riverain's ClearRead™ solutions provide intelligent, enterprise-wide, standard-of-care AI tools for early, efficient detection of lung nodules. ClearRead applications are approved for concurrent

reading, saving radiologists time and steps in enhanced image review. The ClearRead suite significantly improves a clinician's ability to accurately detect disease using patented vessel (CT) and bone (x-ray) suppression technology in thoracic images—for earlier, more efficient detection of lung abnormalities.

“The updated guidelines for CT lung cancer screening recently released by the US Preventive Services Task Force were an important step to improve eligibility and access to screening,” said Mark Koeniguer, Chief Commercial Officer of Riverain Technologies. “However, with a larger patient population, the guidelines also increase the need to track patients over time to ensure that they receive screening and follow-up exams in a timely manner. Volpara Lung software builds on our ability to help clinicians efficiently detect lung nodules and track patients throughout the screening and diagnostic process.”

Ralph Highnam, PhD, Group CEO of Volpara, said: “Riverain’s robust AI solution is a tremendous complement to our lung reporting and tracking capabilities. We are pleased to collaborate with them to improve access to accurate and efficient lung nodule detection among our Volpara Lung users, particularly across the Veterans Integrated Service Network (VISN), where we both provide services for a number of its sites. Our mission as a company is saving families from cancer, and this is an important step along the way.”

The US lung cancer market

The US lung cancer market represents a market of significant commercial potential for Volpara and its nodule detection and diagnostic platform, as lung cancer causes approximately 130,000 deaths each year in the United States alone, including about 60,000 women.

Volpara’s patient reporting, tracking, and risk assessment software, Volpara Lung, covers approximately 8 percent of US lung cancer screening at present. Lung cancer CT screening programs are expanding and developing globally, with about 15M people in the United States now eligible and reimbursement set at approximately US\$250 per scan.

As part of its growth strategy into this market, Volpara is focused on partnering with leading lung imaging, diagnostics, and AI companies to expand its footprint, increase its market share, and deliver a significant uplift in revenue generation.

Authorisation & Additional Information

This announcement was authorised by the Board of Volpara Health Technologies Limited.

ENDS

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparahealth.com
t: +64 21 149 0541

Trevor Chappell
WE Communications
WE-AUVolpara@we-worldwide.com
t: +61 407 933 437

About Volpara Health Technologies Limited (ASX: VHT)

VHT is a health technology software company founded in 2009 on research originally conducted at Oxford University. VHT's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice-management software helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 39 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$132 million, including A\$37 million in April/May 2020, and has made two significant acquisitions in MRS Systems, Inc. (patient tracking software), and CRA Health, LLC (risk and genetics software). VHT is based in Wellington, New Zealand.

For more information, visit www.volparahealth.com